Suppr超能文献

与 COVID-19 大流行期间阿片类药物使用增加相关的因素:一项纳入阿片类药物激动剂治疗患者的前瞻性研究。

Factors Associated With Increased Opioid Use During the COVID-19 Pandemic: A Prospective Study of Patients Enrolled in Opioid Agonist Treatment.

机构信息

From the Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada (TR, ZS); Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada (TR, LN, AW, LT, ZS); Department of Family Medicine, McMaster University, Hamilton, ON, Canada (LN); Medical Sciences Graduate Program, McMaster University, Hamilton, ON, Canada (NS); Northern Ontario School of Medicine, Sudbury, ON, Canada (DCM); Canadian Addiction Treatment Centres, Markham, ON, Canada (DCM); ICES North, Sudbury, ON, Canada (DCM); Health Sciences North Research Institute, Sudbury, ON, Canada (DCM); Department of Medicine, McMaster University, Hamilton, ON, Canada (AW).

出版信息

J Addict Med. 2022;16(4):e257-e264. doi: 10.1097/ADM.0000000000000939. Epub 2021 Nov 16.

Abstract

OBJECTIVES

The opioid use disorder (OUD) crisis in North America has become "an epidemic within a pandemic" in the context of the COVID-19 virus. We aimed to explore the association between the COVID-19 pandemic and changes in opioid use patterns among patients receiving treatment for OUD.

METHODS

We used prospectively collected data from 456 patients attending 31 opioid agonist clinics across Ontario, Canada. All included participants underwent routine urine drug screens (UDSs) both before and after the onset of the COVID-19 pandemic. A paired sample t -test was used to compare the proportion of opioid-positive UDSs collected pre- and post-pandemic, and linear regression analysis was used to explore factors associated with this change.

RESULTS

Participants had a mean age of 39.9 years (standard deviation = 10.9), 52%were male, and 81%were receivingmethadone treatment. The percentage of opioid-positive UDSs increased significantly during the pandemic, on average by 10.6% (95% confidence interval [CI] 8.17, 12.95, P < 0.001). Continued opioid use before the pandemic was associated with 9.43% increase, on average, in the percentage of opioid-positive UDSs during the pandemic (95% CI 3.79, 15.07). Self-reported past-month cocaine (adjusted betacoefficient 6.83, 95% CI 0.92, 12.73) and amphetamine (adjusted beta-coefficient 13.13, 95% CI 5.15, 21.1) use at study entry were also associated with increases in opioid-positive UDSs.

CONCLUSIONS

Increased opioid use is one measure of the negative impact the COVID-19 pandemic has had on individuals with OUD, an already marginalized population. Understanding factors associated with worse outcomes is essential to ensuring that treatment programs appropriately adapt to better serve this population during the pandemic.

摘要

目的

在 COVID-19 病毒大流行的背景下,北美阿片类药物使用障碍(OUD)危机已成为“大流行中的流行病”。我们旨在探讨 COVID-19 大流行与接受 OUD 治疗的患者阿片类药物使用模式变化之间的关联。

方法

我们使用了来自加拿大安大略省 31 个阿片类激动剂诊所的 456 名患者的前瞻性收集数据。所有纳入的参与者都在 COVID-19 大流行之前和之后进行了常规尿液药物检测(UDS)。采用配对样本 t 检验比较了大流行前后收集的阿片类药物阳性 UDS 的比例,并采用线性回归分析探讨了与这种变化相关的因素。

结果

参与者的平均年龄为 39.9 岁(标准差=10.9),52%为男性,81%接受美沙酮治疗。大流行期间阿片类药物阳性 UDS 的比例显著增加,平均增加 10.6%(95%置信区间[CI]8.17,12.95,P<0.001)。大流行前持续使用阿片类药物与大流行期间阿片类药物阳性 UDS 的比例平均增加 9.43%相关(95% CI 3.79,15.07)。研究入组时自我报告的过去一个月可卡因(调整后的贝塔系数 6.83,95% CI 0.92,12.73)和安非他命(调整后的贝塔系数 13.13,95% CI 5.15,21.1)使用也与阿片类药物阳性 UDS 的增加相关。

结论

阿片类药物使用的增加是 COVID-19 大流行对已经处于边缘地位的 OUD 患者产生负面影响的一个衡量标准。了解与更差结果相关的因素对于确保治疗计划在大流行期间适当调整以更好地为这一人群服务至关重要。

相似文献

3
Evidence of increased Fentanyl use during the COVID-19 pandemic among opioid agonist treatment patients in Ontario, Canada.
Int J Drug Policy. 2021 Apr;90:103088. doi: 10.1016/j.drugpo.2020.103088. Epub 2020 Dec 23.
4
Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study.
Subst Abuse Treat Prev Policy. 2021 Mar 5;16(1):22. doi: 10.1186/s13011-021-00358-x.
7
Critical incidents in Colorado's opioid treatment programs: A comparison of the COVID-19 pandemic to previous years.
J Subst Use Addict Treat. 2024 Jun;161:209342. doi: 10.1016/j.josat.2024.209342. Epub 2024 Mar 20.
9
Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees.
JAMA Netw Open. 2023 Oct 2;6(10):e2336914. doi: 10.1001/jamanetworkopen.2023.36914.
10
A population-based time-series analysis of opioid agonist treatment dispensed during pregnancy.
Addiction. 2024 Jun;119(6):1111-1122. doi: 10.1111/add.16459. Epub 2024 Mar 13.

引用本文的文献

3
Addiction Consult Service and Inpatient Outcomes Among Patients with OUD.
J Gen Intern Med. 2024 Nov;39(15):2961-2969. doi: 10.1007/s11606-024-08837-0. Epub 2024 Aug 13.
5
Abstinence duration and psychopathology among addiction outpatients during 18 months of COVID-19.
Front Psychiatry. 2024 Feb 8;15:1339730. doi: 10.3389/fpsyt.2024.1339730. eCollection 2024.

本文引用的文献

1
CDC Warns of Surge in Drug Overdose Deaths During COVID-19.
JAMA Health Forum. 2021 Jan 4;2(1):e210001. doi: 10.1001/jamahealthforum.2021.0001.
3
Sharp increase in depression and anxiety among Brazilian adults during the COVID-19 pandemic: findings from the PAMPA cohort.
Public Health. 2021 Jan;190:101-107. doi: 10.1016/j.puhe.2020.11.013. Epub 2020 Dec 31.
4
Evidence of increased Fentanyl use during the COVID-19 pandemic among opioid agonist treatment patients in Ontario, Canada.
Int J Drug Policy. 2021 Apr;90:103088. doi: 10.1016/j.drugpo.2020.103088. Epub 2020 Dec 23.
8
Addressing racial & socioeconomic disparities in access to medications for opioid use disorder amid COVID-19.
J Subst Abuse Treat. 2021 Mar;122:108214. doi: 10.1016/j.jsat.2020.108214. Epub 2020 Nov 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验